AI startup EvolutionaryScale has secured$142 million in seed funding, led by investors including Nat Friedman, Daniel Gross, and Lux Capital. Both Amazon Web Services (AWS) and NVIDIA's venture capital arm participated in this substantial funding round. Lux Capital's co-founder Josh Wolfe likened EvolutionaryScale's achievements to a 'ChatGPT moment for biology,' highlighting their development of a groundbreaking large language model capable of designing new proteins and biological systems.

EvolutionaryScale aims to deploy its AI across diverse applications, from accelerating drug discovery processes to engineering microbes that can degrade plastic pollution. The company's chief scientist, Alex Rives, emphasised the growing significance of AI in creating innovative biological solutions. That aligns with broader industry trends where AI is increasingly pivotal in advancing biotech and pharmaceutical research.

However, concerns have been raised regarding the potential misuse of generative AI in bioweapons development. Despite these ethical considerations, EvolutionaryScale plans to use its newly secured funding to train its AI models further and expand its team for collaborations within the biotech sector. They have also released the ESM3 models, with the smaller variant open-sourced for non-commercial research, while AWS and NVIDIA will offer the larger ESM3 commercially.

Why does it matter?

One notable achievement highlighted by EvolutionaryScale involves engineering a novel fluorescent protein using their ESM3 model. That protein represents a significant departure from naturally occurring variants, a process typically requiring nature millions of years to evolve. The company's advancements underscore the transformative potential of AI in pushing the boundaries of biological innovation.